文献速递前列腺癌

非转移性去势抵抗性前列腺癌的管理

Managing Nonmetastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2018-08-14

本文综述了非转移性去势抵抗性前列腺癌(nmCRPC)的管理实践。基于PSA动力学和症状的影像学与PSA检测建议及系统治疗启动时机被总结。III期安慰剂对照随机试验显示,恩扎卢胺和阿帕他胺可显著延长PSA倍增时间(DT)≤10个月nmCRPC患者的无转移生存期。

要点

  • nmCRPC定义为PSA升高且睾酮去势水平,传统影像学无转移证据。
  • 影像学和PSA检测的频率及系统治疗启动基于PSA上升动力学和症状。
  • PSA-DT≤10个月的患者可考虑恩扎卢胺或阿帕他胺治疗。

核心结论

  • nmCRPC是异质性疾病,观察可能是部分患者的选择,而恩扎卢胺和阿帕他胺可能适用于PSA-DT≤10个月的患者。

研究设计与样本

  • 文献检索截至2018年7月,包括临床试验和临床实践指南(NCCN、ESMO、EAU、PCCTWG、PC-RADAR)。

主要发现

  • 恩扎卢胺和阿帕他胺在PSA-DT≤10个月的nmCRPC患者III期安慰剂对照随机试验中显著增加无转移生存期。

关键数值与推荐

  • nmCRPC患者PSA-DT≤10个月时可考虑使用恩扎卢胺或阿帕他胺。

临床怎么用

  • 根据PSA上升动力学和症状决定影像学和PSA检测频率及系统治疗启动时机。

局限性

  • 新影像技术和循环肿瘤生物标志物可能重新定义nmCRPC的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. Given recent drug approvals for nmCRPC, with many other therapeutics and imaging modalities being developed, management of nmCRPC is a rapidly evolving field that merits detailed investigation. OBJECTIVE: To review current nmCRPC management practices and identify opportunities for improving care of nmCRPC patients. EVIDENCE ACQUISITION: A literature search up to July 2018 was conducted, including clinical trials and clinical practice guidelines (National Comprehensive Cancer Network, European Society for Medical Oncology, European Association of Urology, Prostate Cancer Clinical Trials Working Group, Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence). Keywords included prostate cancer, nonmetastatic, castration resistance, rising PSA, and biochemical relapse. EVIDENCE SYNTHESIS: Recommendations regarding indications for, and frequency of, imaging and PSA testing, as well as for initiating systemic therapy in nmCRPC are based on PSA rise kinetics and symptoms. Both enzalutamide and apalutamide have been shown to significantly increase metastasis-free survival in phase III placebo-controlled randomised trials in nmCRPC patients with PSA doubling time (DT) ≤10 mo. The expected impact of new imaging techniques in the assessment of nmCRPC is also reviewed. CONCLUSIONS: nmCRPC is a heterogeneous disease; while observation may be an option for some patients, enzalutamide and apalutamide may be appropriate to treat nmCRPC patients with PSA-DT ≤10 mo. The emergence of more accurate imaging modalities as well as circulating tumour biomarker assays will likely redefine the assessment of nmCRPC in the near future. PATIENT SUMMARY: Herein, we review key literature and clinical practice guidelines to summarise the optimal management of patients with prostate cancer and rising prostate-specific antigen despite castrate testosterone levels, but with no evidence of distant metastasis on traditional imaging. New drugs are being developed for this disease setting; novel imaging and tumour biomarker blood tests are likely to define this disease state more accurately.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Mateo J, Fizazi K, Gillessen S, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol. 2018. PMID: 30119985. doi:10.1016/j.eururo.2018.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。